JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266911

Human RNF19B knockout A549 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

RNF19B KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 2 bp deletion in exon 2.

View Alternative Names

E3 ubiquitin-protein ligase RNF19B, FLJ90005, IBR domain containing 3, IBR domain-containing protein 3, IBRDC3, NKLAM, Natural killer lytic-associated molecule, RING finger protein 19B, RN19B_HUMAN, rnf19b

1 Images
Sanger Sequencing - Human RNF19B knockout A549 cell line (AB266911)
  • Sanger seq

Unknown

Sanger Sequencing - Human RNF19B knockout A549 cell line (AB266911)

Homozygous : 2 bp deletion in exon2

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 2 bp deletion in exon 2

Disease

Carcinoma

Product details

Recommended control: Human wild-type A549 cell line (ab255450). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266911-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266911 Human RNF19B knockout A549 cell line", "number":"AB266911-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266911-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266911 Human RNF19B knockout A549 cell line", "number":"AB266911-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
RNF19B
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
  • Do not allow the cell density to exceed 7x104 cells/cm2.
Culture medium

F-12K + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

RNF19B also known as RING finger protein 19B or Dorfin is an E3 ubiquitin-protein ligase that functions through tagging various substrates with ubiquitin marking them for degradation by the proteasome. It has a molecular weight of approximately 54 kDa. This protein appears in various tissues but shows higher expression in the brain spinal cord heart and muscle. RNF19B localizes to the cytoplasm and is known for its role in regulating several cellular processes.
Biological function summary

RNF19B participates in the endoplasmic reticulum-associated degradation (ERAD) pathway and interacts with different co-factors to form functional complexes. It facilitates the removal of misfolded or damaged proteins within the cell thereby maintaining protein homeostasis. The protein's ability to recognize and ubiquitinate misfolded proteins plays a critical part in cellular quality control mechanisms.

Pathways

RNF19B interacts significantly with the ubiquitin-proteasome system and also affects the Parkinson's disease pathway. RNF19B links to key proteins like parkin and CHIP which are involved in the degradation of proteins associated with neurodegenerative diseases. Through these interactions RNF19B modulates cell health and protein turnover highlighting its central role in maintaining cellular balance.

RNF19B exhibits a strong connection to neurodegenerative conditions like amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Mutations or dysregulation of RNF19B can exacerbate cellular stress contributing to disease progression. Additionally RNF19B associates with the protein huntingtin impacting pathways related to Huntington's disease. The protein's ability to regulate misfolded protein degradation links it directly to these disease states suggesting its potential as a therapeutic target.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com